The available evidence suggests that PARP1 mediated AD and PD pathologies could result from several cellular pathways: (i) bioenergetic deficit via NAD+ depletion; (ii) the activation of apoptosis via interaction with tumor suppressor and apoptotic genes such as TP53 and BCL2; (iii) the induction of parthanatos; and (iv) transcription rewiring via the modulation of transcriptional factors [145]. This evidence concerns the gene PARP1 and Parkinson disease.